Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608244 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients
A Phase 2 study, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00608244: Completed Phase 2 study, sponsored by Veloxis Pharmaceuticals.
NCT00608244 is a Phase 2 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608244, a Phase 2 study, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
Primary Outcome
Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.
Interventions
- DRUG Prograf
- DRUG LCP Tacro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
What the finished NCT00608244 record still lists
NCT00608244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Prograf is the first listed.
NCT00608244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608244 about?
NCT00608244 is a clinical study titled "Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients". A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
What is the current status of trial NCT00608244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2007-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00608244?
The interventions under investigation include: Prograf (DRUG), LCP Tacro (DRUG).
Who is sponsoring clinical trial NCT00608244?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608244's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia